BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Targeted kinase inhibitors offer selective treatment for cancers with specific genetic mutations.
• However, patient responses to these therapies vary significantly, even among cancers with identical driver mutations.

Purpose of the Study:

• To investigate the variability in apoptotic rates among cancer cell lines with shared driver oncogenes after kinase inhibitor treatment.
• To identify predictive biomarkers for response to kinase inhibitors.

Main Methods:

• Assessed apoptosis rates in cancer cell lines with common driver oncogenes upon treatment with corresponding kinase inhibitors.
• Measured pre-treatment RNA levels of the BH3-only pro-apoptotic protein BIM.
• Correlated BIM RNA levels with apoptosis and clinical response in EGFR-mutant lung cancer specimens.

Main Results:

• Significant variation in kinase inhibitor-induced apoptosis was observed, despite comparable target inhibition.
• Pre-treatment BIM RNA levels strongly predicted apoptosis induction by EGFR, HER2, and PI3K inhibitors in relevant cancer models.
• BIM RNA levels did not predict response to conventional chemotherapies.
• In EGFR-mutant lung cancer, BIM RNA levels correlated with response and duration of clinical benefit from EGFR inhibitors.

Conclusions:

• BIM RNA levels serve as a potential predictive biomarker for response to single-agent kinase inhibitors in various oncogene-addiction contexts.
• Assessing BIM levels in treatment-naïve biopsies may help personalize targeted therapy selection and predict patient benefit.